Haselmeier released GONAL-f® 2.0 after being approved by the European Medicines Agency (EMA).
The new version is based on Haselmeier’s disposable, multi-use pen Axis-D platform, which has been enhanced to make it easier to hold. It also has a larger screen for improved readability.
These changes will help patients to clearly view their pre-set dosage, reassuring them that they have taken the correct amount. This is complemented further by a graduated scale on the transparent cartridge.
Merck’s original design features have been retained and improved, including dosing accuracy and individual dosing.
Haselmeier’s key account manager Klaus Schmid comments: "We see this as an important next step in the future partnership with Merck to bring technology and life cycle management evolution to the existing portfolio of Merck devices."
The company’s strategic product manager Stefan Gaul adds: "We are happy about the opportunity to support Merck with the development of the next generation of GONAL-f® pen design. We are convinced that this new pen will be appreciated by patients, due to its simple and convenient use, as well as its sophisticated design."